Education
About Us
Working with TipRanks
Follow Us
Asia Green Biotechnology Corp. (TSE:ASIA)
:ASIA
RESEARCH TOOLSreports
Top Page
Asia Green Biotechnology Corp.
(ASIA)
31Underperform
Asia Green Biotechnology Corp. (ASIA) vs. S&P 500 (SPY)
Market Cap
C$543.71K
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth-162.16%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength65
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding36,247,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Asia Green Biotechnology Corp. Business Overview & Revenue Model
Company DescriptionAsia Green Biotechnology Corp. (ASIA) is a biotechnology company focused on the development and commercialization of plant-based technologies and products. The company primarily operates in the agricultural sector, offering innovative solutions tailored towards crop enhancements and sustainable agriculture practices. ASIA's core products include genetically modified crops, biopesticides, and biofertilizers that aim to increase crop yields, improve plant resistance to diseases, and reduce the ecological footprint of agricultural practices.
How the Company Makes MoneyAsia Green Biotechnology Corp. makes money through the sale of its biotech agricultural products, including genetically modified seeds, biopesticides, and biofertilizers to farmers and agricultural companies. The company also generates revenue by licensing its proprietary biotechnology innovations to other agricultural firms and entering into strategic partnerships for research and development. Additionally, ASIA may receive government grants and subsidies aimed at promoting sustainable agricultural practices, which can contribute to its earnings.
Asia Green Biotechnology Corp. Financial Statement Overview
Summary
Asia Green Biotechnology Corp. is experiencing severe financial distress with no revenue, high losses, negative equity, and significant cash outflows. The firm’s financials highlight substantial operational and financial challenges, with no current pathway to profitability or growth evident from the data.Income Statement
The company has reported no revenue over the assessed periods, leading to negative net income and EBIT margins. This indicates a lack of revenue generation ability or early-stage operations. The firm's profitability margins are negative, reflecting ongoing losses and operational challenges.10
Very Negative
Balance Sheet
The balance sheet is currently weak, with negative stockholders' equity suggesting liabilities exceed assets, indicating financial instability. The debt levels are high compared to equity, which implies significant leverage and potential solvency risks.15
Very Negative
Cash Flow
Cash flows are consistently negative, with significant operating cash outflows and no positive free cash flow, signaling cash burn and potential liquidity issues. The company has financed operations through debt and equity but lacks operational cash generation.20
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| -241.51K | -144.74K | -179.21K | -523.24K | -552.83K | -687.18K | EBITDA |
| -279.97K | 23.16K | 0.00 | -523.24K | -552.83K | -687.18K | Net Income Common Stockholders |
| -350.41K | -221.17K | -198.31K | -525.80K | -552.83K | -807.18K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 484.15K | 1.31K | 12.40K | 67.27K | 381.15K | 1.02M | Total Assets |
| 554.12K | 65.34K | 68.18K | 116.30K | 441.38K | 1.05M | Total Debt |
| 0.00 | 237.41K | 225.00K | 150.00K | 0.00 | 0.00 | Net Debt |
| -484.15K | 236.09K | 212.60K | 82.73K | -381.15K | -1.02M | Total Liabilities |
| 130.01K | 527.31K | 343.28K | 193.09K | 28.33K | 88.95K | Stockholders Equity |
| 424.11K | -461.98K | -275.10K | -76.79K | 413.05K | 965.88K |
| Cash Flow | Free Cash Flow | ||||
| -2.25K | -36.09K | -129.87K | -463.88K | -640.78K | -670.67K | Operating Cash Flow |
| -2.25K | -36.09K | -129.87K | -463.88K | -640.78K | -670.67K | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 0.00 | 25.00K | 75.00K | 150.00K | 0.00 | 1.21M |
Asia Green Biotechnology Corp. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Performance Comparison
TSE:ASIA
Asia Green Biotechnology Corp.
0.02
0.00
0.00%
TSE:WEED
Canopy Growth
1.46
-9.86
-87.10%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.